Skip to main content
179 results:
71. SphingoTec launches point-of-care test for bio-ADM, a biomarker for life threatening endothelial dysfunction  
Diagnostics company SphingoTec GmbH (“SphingoTec”) today announced the launch of its IB10 sphingotest® bio-ADM®, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of…  
72. Sphingotec’s critical care biomarkers early diagnose risk of loss of endothelial, kidney and heart function in severely ill COVID-19 patients  
Diagnostics company SphingoTec GmbH (“sphingotec”) announced today the results of a working group meeting of clinical experts that discussed the utility of sphingotec’s diagnostic solutions for acute…  
73. The cardiac depressant factor DPP3 is predicting organ failure in burn patients  
Diagnostics company SphingoTec GmbH (“sphingotec”) and 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) announced today the publication of new data showing that high blood levels of Dipeptidyl Peptidase 3…  
74. sphingotec expands leadership team and appoints Achim Plum as Managing Director and Chief Commercial Officer  
Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf, Germany) today announced that it has appointed Dr. Achim Plum as Managing Director and Chief Commercial Officer (CCO) of the company.  
75. SphingoTec's endothelial function biomarker bio-ADM® improves risk stratification of sepsis patients at ICUs  
Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf Germany) today reported on new data on the utility of endothelial function biomarker bioactive Adrenomedullin (bio-ADM®).   
76. Bioactive Adrenomedullin, measured with sphingotec’s bio-ADM® assay plays a key role in septic shock patients as top-line results of AdrenOSS-2 Phase II Study indicate  
Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf, Germany) today announced that data from the AdrenOSS-2 study indicate a modulating role of bioactive Adrenomedullin in septic…  
77. Novel Data on SphingoTec's Biomarkers for acute and critical care setting to be presented at AKI & CRRT 2020  
SphingoTec GmbH (“sphingotec”) today announced that novel data on its acute care biomarkers Proenkephalin (penKid®) and Dipeptidyl Peptidase 3 (DPP3) will be presented at the 25th International…  
78. SphingoTec's biomarker penKid® shows best representation of true glomerular filtration rate and has utility in patients with sever burns two studies show  
Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf Germany) today announced the publication of two studies demonstrating that its kidney function biomarker Proenkephalin (penKid®) is the…  
79. Hitado GmbH becomes Nexus IB10 distributor for Sphingotec in Germany an Switzerland  
Hitado GmbH (Hitado), a Sysmex point-of-care subsidiary, and SphingoTec GmbH (sphingotec) have signed an exclusive distribution agreement for the commercialisation of the Nexus IB10 diagnostic…  
80. SphingoTec launches IVD Test for Kidney Function Biomarker penKid® on Nexus IB10 POCT Platform  
Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf near Berlin, Germany) today announced the launch of its IB10 sphingotest® penKid®, a CE-IVD-marked point-of-care test for Proenkephalin…  
Search results 71 until 80 of 179